The purpose of this paper was to determine the effects of cold ischemia on the detection of ERBB2, also known as human epidermal growth factor receptor 2 (Her2), by immunohistochemistry (IHC) and by two methods of in situ hybridization (ISH) in breast cancer tissue. The effects of using different in situ hybridization scoring criteria were also investigated.
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.
Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR
Purpose
Conclusion
Generally, there was agreement in ERBB2 amplification status between fluorescence in situ hybridization (FISH) and dual color ISH, but differences between scoring methods were noted. ERBB2 IHC showed the highest concordance with FISH and dual color ISH results when the single probe scoring criteria was used. Importantly, dual color ISH generated a stronger signal intensity than FISH for both ERBB2 and CEP17 (chromosome 17), regardless of cold ischemia time. Cold ischemia times of >3 h significantly decreased the FISH signal intensities for ERBB2 in stroma and chromosome 17 in stroma and tumor compared to intensities after <1 h cold ischemia time.
Studies (1)
Purpose
The purpose of this study was to determine the effects of cold ischemia on the detection of ERBB2, also known as Her2, by IHC and by two methods of ISH (PathVysion FISH and the INFORM Her2 dual in situ DNA probe assay) in breast cancer tissue. The effects of using different ISH scoring criteria were also investigated. A total of 84 breast carcinoma specimens were used in this study, and IHC and ISH assays were performed using a tissue microarray.
Summary of Findings
For all cold ischemia times, FISH and dual color ISH were able to detect ERBB2 amplification with 100% concordance when either the ASCO/CAP dual probe or the FDA package insert scoring methods were employed. When the ASCO/CAP single probe scoring criteria was used, FISH and dual color ISH results generally still agreed, but amplification status of 3 of the 9 amplified cases changed to equivocal or non-amplified. These 3 cases all had a cold ischemia time of <1 h. ERBB2 IHC showed the highest concordance with FISH and dual color ISH results when the single probe scoring criteria was used. Other minor discrepancies among the scoring methods and between FISH, dual color ISH, and IHC were observed, the most common being an equivocal score for IHC while FISH and dual color ISH determined a non-amplified status, regardless of scoring method. Importantly, while dual color ISH generated a stronger signal intensity than FISH for both ERBB2 and CEP17, regardless of cold ischemia time (p<0.05, all), cold ischemia times of up to 3 h did not significantly decrease signal intensities for either assay. Cold ischemia times of >3 h did however significantly decrease the FISH signal intensities for ERBB2 in stroma and chromosome 17 in stroma and tumor compared to intensities after <1 h cold ischemia time (p<0.05, all).
Biospecimens
TissueBreastPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinTissue microarrayProteinImmunohistochemistryDNAFISHDNAIn situ hybridizationDNATissue microarrayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Cold ischemia time 1-2 h2-3 h<1 h>3 hIn situ hybridization Specific Data handling ASCO/CAP dual-probe scoringASCO/CAP single-probe scoringFDA in-situ hybridization package insertIn situ hybridization Specific Detection method Dual colorFluorescenceIn situ hybridization Specific Targeted nucleic acid CEP17ERBB2 (HER2)FISH Specific Data handling ASCO/CAP dual-probe scoringASCO/CAP single-probe scoringFDA in-situ hybridization package insertFISH Specific Targeted nucleic acid CEP17ERBB2 (HER2)Immunohistochemistry Specific Targeted peptide/protein ERBB2 (HER2)Immunohistochemistry Specific Technology platform Dual color in situ hybridizationFISH